GeneDx Resets 2026 Guidance on Genome Mix Shift, Cuts $25M OpEx
Exome-to-genome mix pressure and non-core softness drive a 12% revenue guide cut; management doubles down on ARR and cost levers.
SMFR · Earnings Call · 2026-05-04
Q1 2026: A Reset in Expectations
GeneDx Holdings Corp. (ticker SMFR in the dataset) started 2026 with a disappointing revenue miss and a substantial guidance cut, reflecting a mix shift that management admits caught them off guard. Total Q1 revenue came in at $102.3M, $12M below expectations, with exome/genome revenue of $90.6M (up 27% year-over-year) and volume of 27,488 tests (up 34%). The company reduced full-year 2026 revenue guidance to $475–490M from a prior ~$550M midpoint, a 12% cut, while maintaining volume growth of at least 30% and gross margins around 70%. As Katherine Stueland put it, “We have line of sight to at least 30% volume growth at approximately 70% gross margins on the exome and genome portfolio, and we are committed to a return to profitability on the balance of the year.” — Katherine Stueland, President and Chief Executive Officer · 2026-05-04 This reset echoes the global keyword commercial readiness that has been rising across the market, but here the challenge is not readiness — it's the economics of a product transition.Genome Mix Shift: The Core Driver
The primary culprit is the accelerated shift from exome to genome in the outpatient geneticist channel. Genome was roughly 40% of outpatient volume in Q1, double the year-ago level, but its average reimbursement rate is only about half that of exome. Kevin Feeley clarified, “The blended ARR came in approximately $200 below expectations. I want to be very clear: on a like-for-like basis, ARR by product is relatively unchanged.” — Kevin Feeley, Chief Financial Officer · 2026-05-04 The issue is mix, not price. The company expects to manage this through its new Reflex product, which combines exome with a reflex-to-genome option at a reimbursement rate closer to exome. Feeley added, “we think it can get towards parity with exome.” — Kevin Feeley, Chief Financial Officer · 2026-05-04 This is a delicate balancing act: they want to ride the growing demand for genome while protecting unit economics. The stock market's own keyword momentum shows earnings power as a top theme, and GeneDx's near-term profitability hinges on exactly this kind of pricing discipline.Non-Core Adjustments and OpEx Discipline
Beyond the mix shift, $6.5M of the revenue miss came from non-core lines: Fabric (interpretation-as-a-service) and biopharma/data. Fabric has been repositioned toward international markets, resulting in a $31.3M non-cash impairment and a lower revenue contribution for 2026. Biopharma suffered from longer-than-expected sales cycles. Management cut $25M of planned OpEx for the year, but stressed this is a reallocation, not a reduction in current spending. As Stueland noted, “We have taken the decisive step of cutting $25 million of OpEx for the year” — Katherine Stueland, President and Chief Executive Officer · 2026-05-04 and reallocated it toward the three biggest levers: utilization, unit economics, and product leadership. This disciplined approach aligns with the global focus on probability of success — the company is now underwriting only high-confidence initiatives.I recognize that resetting expectations is difficult, but it also gives us all great clarity and conviction in our ability to deliver on our commitment.